It is another "me too" in an already crowded market. This tiny company is crazy for trying to get into this market space. Baxter runs the hemophilia market and they have the money and the reputation to stay number one. Cangene hasn't even begun to try and tap into the hemophilia space. They have no MSLs on board as of yet to begin grooming the market, no patient advocates hired to start building relationships with the Foundations, and they just hired a NSD with IVIG experience thinking he is going to be able to pull this all together. This company does everything too late and they wonder why sales suck. I wonder if the commercial sales force will even be here 12 months from now.